JAM
OTLK icon

JW Asset Management’s Outlook Therapeutics OTLK Stock Holding History

JW Asset Management’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-32
Closed -$14K – 38
2017
Q1 		$14K Hold
32
– – ﹤0.01% 42
2016
Q4 		$16K Buy
+32
New +$17.9K 0.01% 38

Other funds holding OTLK

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

JW Asset Management's OTLK Position: Q2 2017 in Review

JW Asset Management sold out of Outlook Therapeutics (OTLK) in Q2 2017, closing a stake of 32 shares — an estimated $14K sold.

JW Asset Management first reported a position in OTLK in Q4 2016 and held it in 2 quarters. The position peaked at $16K in Q4 2016. 16 funds tracked by Wall St. Rank hold OTLK as of Q2 2017.

  • JW Asset Management reported no remaining Outlook Therapeutics position as of Q2 2017 after selling out during the quarter.
  • JW Asset Management sold 32 Outlook Therapeutics shares in Q2 2017, an estimated $14K.
  • JW Asset Management first reported a position in Outlook Therapeutics in Q4 2016 and held it in 2 quarters.
  • JW Asset Management's Outlook Therapeutics position peaked at $16K in Q4 2016.
  • 16 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q2 2017.

Based on JW Asset Management's 13F filing for Q2 2017, filed 4 Aug 2017.